Prime Unicorn Index Q3 2025 Reconstitution Update

Just a couple of weeks ago, the Prime Unicorn Index underwent its quarterly reconstitution. While the full report dives deep into the numbers, we’re breaking down a few quick highlights from the Prime Unicorn 30—our flagship index tracking the 30 most valuable U.S. private venture-backed companies.

High-Level Overview

This quarter’s reconstitution brought two new names into the Prime Unicorn 30:

  • xAI Holdings Corp. (Valuation: $92.9B)
  • Ripple Labs, Inc. (Valuation: $12.4B)

They replaced ServiceTitan, which met its post-IPO lockup period, and Hinge Health, which fell below the ranking threshold following its public offering.

As of July 16, 2025:

  • Total Index Market Value: $797B
  • Largest Component: SpaceX ($288.9B)
  • Median Component Valuation: $8.9B
  • Top 10 Components make up 82% of the total index valuation
  • YTD Return: +37.89%
  • Annualized Volatility: 22.31%

Story of the Quarter: The Musk Trifecta

With xAI’s debut, Elon Musk now has three companies in the Prime Unicorn 30—SpaceX, Neuralink, and xAI—representing a combined valuation well north of $394 billion. That’s nearly half the index’s total valuation, though their combined weighting is a bit lower due to the modified market cap methodology, which equals roughly 22.4%.

The addition of xAI marks a growing trend: the rising influence of AI-first companies in the private markets—especially those with consumer platforms and bold ambitions.

Composite Index Update

The broader Composite Index welcomed several new additions this quarter:

  • xAI Holdings Corp. – $92.85B
  • Cyberhaven, Inc. – $1.03B
  • Nourish, Inc. – $1.31B
  • Transcarent, Inc. – $2.70B
  • Nexamp, Inc. – $1.33B
  • Cart.com, Inc. – $1.71B
    • Reintroduced; previously removed for slipping below $1B in Q1 2024
  • Gecko Robotics, Inc. – $1.20B
  • Juniper Square, Inc. – $1.01B
  • MaintainX Inc. – $2.56B

Removed from the index:

  • ServiceTitan, Inc.
    • Reason for removal: Public
  • Pollen, Inc.
    • Reason for removal: <$1B
  • Tessera Therapeutics, Inc.
    • Reason for removal: <$1B
  • Mythical, Inc.
    • Reason for removal: <$1B

📊 Looking to go more in-depth?
Download the full Q3 2025 Reconstitution Report to explore deal data, valuation movements, and key index insights.